Oncologist Attitudes May Factor into Underutilization of Genetic Counseling, Testing in Black Women with Breast CancerNovember 30th 2021
Although White women and Black women carry similar rates of pathogenic variants, a study found that White women were almost 5 times more likely to undergo genetic counseling and testing.
Nurse Intervention Helps Patients Maintain Physical Activity, Quality of Life During Cancer TreatmentOctober 26th 2021
The implementation of the Oncology Nursing Society’s new Get Up, Get Moving Program helped patients increase their daily step intake and maintain their health-related quality of life.
New Clinical Trial Will Assess Novel ADC in Drug Resistant HER2+ Breast CancerOctober 23rd 2021
The recently launched phase 2 ACE-Breast03 seeks to appraise the efficacy and safety of the novel antibody-drug conjugate, ARX788, in patients with metastatic HER2-positive breast cancer whose disease is resistant to previous targeted therapies.
COVID-19 Vaccine Elicits Similar 6-Month Antibody Response in Both Patients with Solid Tumors and the General PopulationOctober 5th 2021
The Pfizer-BioNTech COVID-19 vaccine induces similar levels of COVID-19 antibodies in patients with solid cancer compared with people without cancer.
Barriers in BIPOC Populations Diagnosed With Breast CancerSeptember 28th 2021
BIPOC patients diagnosed with breast cancer often face additional barriers–like health disparities, health literacy, and lack of knowledge of the psychosocial effects–in comparison to other ethnic groups.
Four-Year Follow-Up Shows Neoadjuvant Carboplatin/Paclitaxel Combo Improves Event-Free Survival in TNBCSeptember 26th 2021
A 4-year follow-up of patients with treatment-naïve triple-negative breast cancer who received carboplatin plus neoadjuvant paclitaxel, followed by doxorubicin and cyclophosphamide, suggests that the regime induces superior pathological complete response and event-free survival.
CDK4/6 Inhibitors Gain Momentum in Early-Stage Breast Cancer, But More Research is Still NeededAugust 5th 2021
CDK4/6 inhibitors have demonstrated promise in treating patients with estrogen receptor (ER)–positive, HER2-negative breast cancer in both a neoadjuvant and adjuvant setting.
Ultralow Risk 70-Gene Promises Superior Survival Outcomes in Patients with Early-Stage Breast CancerJune 27th 2021
Regardless of clinical risk, the survival prognosis of patients with early-stage breast cancer is high amongst those who have ultralow risk disease indicated by a 70-gene signature.
Olaparib Is Beneficial 1 Year After Standard of Care Therapies in BRCA, High-Risk, Early HER2- Breast CancerJune 4th 2021
Patients with BRCA1/2-mutant, early HER2-negative breast cancer at a high risk of recurrence saw a clinically meaningful benefit 1 year after standard of care when treated with olaparib.
T-DM1 Toxicity Management in Breast CancerApril 5th 2021
Data from the pivotal phase 3 KATHERINE has led to the addition of ado-trastuzumab emtansine to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it.
FDA Defers Decision on Pembrolizumab for TNBC: Here's WhyMarch 30th 2021
Ahead of the Prescription Drug User Fee Act action date for the application, the regulatory agency’s Oncologic Drugs Advisory Committee voted 10 to 0 that a decision be deferred until further findings from KEYNOTE-522 trial become available.
Palbociclib/Letrozole Improves Survival in HR+ Metastatic Breast CancerMarch 26th 2021
Palbociclib in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor–positive, HER2-negative, metastatic breast cancer vs letrozole alone in the first-line setting.
Immunotherapy and ADCs Make Headway in Metastatic TNBCMarch 22nd 2021
Anthracyclines and taxanes remain a backbone in the early-stage setting of triple-negative breast cancer as further evaluations of immunotherapy in the neoadjuvant and adjuvant settings needs to be conducted—efforts that will continue to shape the treatment paradigm.
Study Explores Actionable Pathologic Variants in Caribbean Women With Breast or Ovarian CancerMarch 11th 2021
One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.